Please assess the completion status of the following clinical trial:

Trial Title: REtinal and VIsual Cortical Response in Early PSYchosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
1. Inclusion Criteria:~   1. All groups~      Age and gender matching~      Age between 18 and 40~      Enrolled in a social security plan~      Normal or corrected-to-normal visual acuity verified by Monoyer test~      In women of childbearing age: negative urine pregnancy test at the inclusion visit~      Person who has received and understood prior information about the study~      Person who has given free and informed written consent prior to any participation in the study~  2. Healthy control group (HC; n=30)~      Met all groups criteria~      No current disorders as assessed by the MINI global assessment~      No lifetime (hypo)manic episodes or psychotic disorders and current~      No current or past disorders by CAARMS assessment~      No current disorders according to ICD-10 criteria~      No positive family history (parents/first degree) for affective affective, non-affective psychoses or major affective disorders~      No regular use (more than 3 psychotropic medications: benzodiazepines, hypnotics,antidepressants, antipsychotics or mood regulators or psychostimulants) during the past last 12 months~  3. High clinical risk group for psychosis (CHRP; n=30)~      Met all groups criteria, Assessment at CAARMS:~     * Attenuated positive symptoms (APS)~     * OR Brief Intermittent Psychotic Symptoms (BIPS)~     * OR Attenuated psychosis of sub-laminar frequency~     * OR sub-laminar attenuated psychosis~      Antipsychotic treatment with a cumulative dose of equivalent chlorpromazine \<2500mg lifetime (1)~  4. First Episode Psychosis (FEP; n=30)~   All-group criteria met CAARMS assessment: Psychosis/antipsychotic treatment threshold treatment threshold achieved at CAARMS~   Antipsychotic treatment with a cumulative dose of equivalent chlorpromazine \<2500mg lifetime (1)~2. Exclusion Criteria (all groups):~Impairment of the subject that makes it difficult or impossible to participate in the or comprehension of the information provided to him/her~Dyslexia~Substance use disorder according to CIM-10~Neurological history including progressive neurological pathology~Progressive retinal disease~Chronic glaucoma~Ophthalmologic pathology affecting visual acuity~Current ocular infection~Major under guardianship, curatorship or safeguard of justice~Pregnant or breastfeeding women~Persons in a life-threatening emergency situation~Result of the preliminary medical examination incompatible with the research~Patient presenting a suicidal risk.~Criteria incompatible with the use of the Retinaute:~* Allergy to silver~* Known or suspected allergy to any of the following components:~polyamide, polyester, elastane, latex, rubber, silicone, or any synthetic material as well as to cotton in case the device is used without the device is used without a protective head covering~* Sensory disorders making the patient insensitive to pain on the skin.~* Behavioral problems making the patient extremely agitation or aggression.~* Mental disorders incompatible with the use of the device.~* Seizure disorder.~* Open wound in an area covered or wrapped by the device.~* User at high risk of contagion.~* Wearing an implantable medical device (e.g. pacemaker)~* Pregnant women, women in labor or nursing mothers.~* Allergy or skin sensitivity to one of the components of the cream Elefix or equivalent on the market: coconut oil, egg oil, propylene glycol egg oil, propylene glycol, glycerin, lanolin...~* Allergy or skin sensitivity to one of the components of the cream NuPrep or market equivalent~Participation in another interventional study (exclusion period included)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (HC) (Type: EXPERIMENTAL): n=90
- Clinical High Risk of Psychosis (CHRP) (Type: EXPERIMENTAL): n=30
- First Episode Psychosis (FEP) (Type: EXPERIMENTAL): n=30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues